Kangtai Biological: Sabin strain inactivated polio vaccine approved for market.

Kangtai Biotech announced that its wholly-owned subsidiary, Beijing Minhai Bio-technology Co., Ltd., has received the "Drug Registration Certificate" issued by the National Medical Products Administration. The Sabin strain inactivated polio vaccine has been approved for market, used for preventing acute infectious diseases caused by the poliovirus. The approval of this vaccine will further enrich the company's product lineup, strengthen the company's core competitiveness, but the timing of the product's market launch is uncertain. Investors are advised to make cautious decisions and be aware of investment risks.